MSCI finalized new rules that could exclude companies like Strategy and Metaplanet, which mainly hold investments rather than operate traditional businesses, from its global equity indexes starting November 30. This change could trigger forced selling by index funds, potentially causing about $2.8 billion in outflows from Strategy's stock, though it won't affect the companies' bitcoin holdings directly. The move reflects MSCI's effort to distinguish operating businesses from investment vehicles, impacting demand for shares and possibly limiting these firms' ability to raise capital for further bitcoin purchases. The final list of affected companies will be announced on November 11.
MSCI's new rules affecting bitcoin treasury firms Strategy and Metaplanet provide context for market conditions. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 16, 2026 15:21 WIB: out of 50 priced major cryptocurrencies tradable on Pluang, 45 rose and 3 fell today. Notable movers include KSM (Kusama) at Rp83.272 with a 1-day change of +8.08% and 100% buy order activity, XTZ (Tezos) at Rp5.733 with +7.97% and 77% sell order activity, and UNI (Uniswap) at Rp133.683 with +7.55% and 56% buy order activity.
Vereigen Media's Verified Content Engagement (VCE) solution won Gold at the 2026 TITAN Business Awards for improving B2B lead quality through first-party data, human verification, and engagement validation. This approach helps marketing teams deliver...
UBS Group AG has officially notified that it holds 7,768,727 shares in Bang & Olufsen A/S, representing 5.27% of the company's total share capital and voting rights as of October 9, 2026. This disclosure is made in compliance with the Danish Capital ...
Norsk Hydro will publish its third-quarter 2026 financial results on October 23, 2026, at 07:00 CEST. The company's CEO and CFO will present the results via a live webcast at 08:30 CEST the same day, allowing investors to ask questions online. There ...
On October 14, 2026, Michael Brierley, a Non-Executive Director of Admiral Group plc, and his wife Rachel Brierley acquired shares of the company through a dividend reinvestment trading plan. The transactions involved purchasing ordinary shares at pr...
The FDA has approved Roche's Enspryng (satralizumab) as the first and only at-home subcutaneous treatment for adults with thyroid eye disease (TED). This approval follows positive results from Phase III SatraGO-2 trials showing significant reductions...
